Physician profile
Adel Asaad
NPI 1316387368
$4,979.78
in general payments reported to CMS, 2019-2025
30 companies · $1,242 in 2025
The $1,242 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $239 · 2020: $418 · 2021: $642 · 2022: $441 · 2023: $1,367 · 2024: $631 · 2025: $1,242.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,265 · Travel and Lodging: $815 · Education: $116 · Gift: $43.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,265.16 |
| Travel and Lodging | $814.71 |
| Education | $116.38 |
| Gift | $43.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,069.16 | 2023-2025 | Da Vinci Surgical System |
| United Therapeutics Corporation | $558.11 | 2019-2025 | Tyvaso, Tyvaso, Orenitram |
| Actelion Pharmaceuticals US, INC. | $516.85 | 2020-2025 | Opsumit, Uptravi |
| Insmed, INC. | $494.52 | 2022-2025 | Arikayce, Brinsupri |
| Glaxosmithkline, LLC. | $338.26 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Ethicon INC. | $227.46 | 2021-2023 | Monarch Platform |
| Merck Sharp & Dohme LLC | $224.88 | 2024-2025 | Winrevair, Zerbaxa, Recarbrio |
| Astrazeneca Pharmaceuticals LP | $221.14 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $197.43 | 2020-2024 | |
| Regeneron Healthcare Solutions, INC. | $157.44 | 2023-2025 | Dupixent |
| Janssen Pharmaceuticals, INC | $138.82 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $122.69 | 2024-2025 | Glassia |
| Veran Medical Technologies, INC. | $107.02 | 2019 | |
| Fujifilm Healthcare Americas Corporation | $95.23 | 2024 | Fujifilm |
| Bayer Healthcare Pharmaceuticals INC. | $93.66 | 2020-2024 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $83.79 | 2023-2025 | |
| Shionogi INC | $43.56 | 2022 | |
| Verona Pharma, INC. | $43.19 | 2025 | Ohtuvayre |
| Pulmonx Corporation | $35.27 | 2022 | |
| Baxter Healthcare | $34.31 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Nabriva Therapeutics, Plc | $24.51 | 2021-2022 | |
| Vapotherm INC | $21.90 | 2022 | |
| Ambu INC. | $19.19 | 2024 | |
| Amgen INC. | $18.78 | 2025 | Tezspire |
| Resmed Corp | $17.23 | 2023 | |
| Abbvie INC. | $16.41 | 2022 | |
| Tactile Systems Technology INC | $15.53 | 2024 | Flexitouch Plus, Entre Plus |
| Paratek Pharmaceuticals, INC. | $15.46 | 2022 | |
| Electromed, INC. | $14.11 | 2022 | |
| Grifols USA, LLC | $13.87 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adel Asaad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.